Kineta Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
KA Nasdaq 8731 https://kinetabio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Kineta Inc

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial - Apr 8th, 2024 8:01 pm
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update - Mar 21st, 2024 8:02 pm
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported - Mar 12th, 2024 12:00 pm
Kineta Announces Restructuring and Exploration of Strategic Alternatives - Feb 29th, 2024 1:30 pm
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium - Feb 22nd, 2024 1:30 pm
Kineta to Present at Upcoming Investor Conferences - Feb 14th, 2024 1:30 pm
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series - Feb 7th, 2024 1:30 pm
KA: Phase I/II Update - Jan 29th, 2024 9:32 am
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors - Jan 17th, 2024 1:30 pm
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event - Jan 4th, 2024 1:30 pm
Life Science Investor Forum: Presentations Now Available for Online Viewing - Dec 15th, 2023 1:35 pm
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer - Dec 13th, 2023 1:30 pm
Life Science Investor Forum Agenda Announced for December 14th, 2023 - Dec 12th, 2023 6:02 pm
Kineta to Present at the Life Sciences Investor Forum December 14th - Dec 12th, 2023 2:24 pm
Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023 - Nov 28th, 2023 1:30 pm
Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit - Nov 9th, 2023 1:30 pm
KA: Third Quarter Results - Nov 7th, 2023 10:00 am
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting - Nov 6th, 2023 1:30 pm
Kineta Insider Purchases Yet To Pay Off Regardless Of Recent Strength - Nov 4th, 2023 12:40 pm
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Nov 3rd, 2023 8:01 pm